NASDAQ:CGEN Compugen (CGEN) Stock Price, News & Analysis $1.83 +0.01 (+0.55%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$1.80▼$1.8950-Day Range$1.56▼$2.1052-Week Range$0.53▼$3.03Volume171,396 shsAverage Volume458,269 shsMarket Capitalization$163.31 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Compugen alerts: Email Address Compugen MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside118.6% Upside$4.00 Price TargetShort InterestBearish1.94% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom $0.07 to ($0.11) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.58 out of 5 starsMedical Sector842nd out of 910 stocksBiological Products, Except Diagnostic Industry146th out of 155 stocks 3.5 Analyst's Opinion Consensus RatingCompugen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCompugen has received no research coverage in the past 90 days.Read more about Compugen's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.94% of the outstanding shares of Compugen have been sold short.Short Interest Ratio / Days to CoverCompugen has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Compugen has recently increased by 2.98%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCompugen does not currently pay a dividend.Dividend GrowthCompugen does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CGEN. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 3 people have searched for CGEN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows3 people have added Compugen to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Compugen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.50% of the stock of Compugen is held by insiders.Percentage Held by InstitutionsOnly 12.22% of the stock of Compugen is held by institutions.Read more about Compugen's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Compugen are expected to decrease in the coming year, from $0.07 to ($0.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Compugen is -9.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Compugen is -9.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCompugen has a P/B Ratio of 2.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Compugen's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIYou missed the class - here’s your second chanceIt’s time to start your Weekend Side Hustle Right now, some of the HARDEST working folks are getting destroyed by inflation. And that’s left folks looking anywhere they can to generate extra income to cover the bills. It’s almost impossible to keep up with the ever rising costs of living anymore… Most folks think that the ONLY way to generate extra income is by picking up a second job at Costco… Or working overtime hours and late weekend nights. But with what I’m about to share…Click here and I’ll give you the details. About Compugen Stock (NASDAQ:CGEN)Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Read More CGEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CGEN Stock News HeadlinesAugust 29, 2024 | prnewswire.comCompugen to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 27, 2024 | money.usnews.comCompugen LtdSeptember 7, 2024 | Sasco Gold LLC (Ad)Say Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... August 16, 2024 | markets.businessinsider.comTruist Financial Keeps Their Buy Rating on Compugen (CGEN)August 13, 2024 | finance.yahoo.comCompugen Ltd. (CGEN)August 11, 2024 | finance.yahoo.comParty Time: Brokers Just Made Major Increases To Their Compugen Ltd. (NASDAQ:CGEN) Earnings ForecastsAugust 10, 2024 | seekingalpha.comCompugen Ltd. (CGEN) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | markets.businessinsider.comCompugen: Strong Buy on Promising Trials, Strategic Alliances, and Solid FinancialsSeptember 7, 2024 | Sasco Gold LLC (Ad)Say Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... August 7, 2024 | finance.yahoo.comCompugen Ltd. (NASDAQ:CGEN): When Will It Breakeven?August 6, 2024 | prnewswire.comCompugen Reports Second Quarter 2024 ResultsAugust 6, 2024 | msn.comCompugen Q2 2024 Earnings PreviewJuly 31, 2024 | benzinga.comCheckpoint Therapeutics (NASDAQ:CKPT) Stock Quotes, Forecast and News SummaryJuly 29, 2024 | finanznachrichten.deCompugen Ltd.: Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid TumorsJuly 29, 2024 | prnewswire.comCompugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid TumorsJuly 23, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Compugen (CGEN)July 23, 2024 | prnewswire.comCompugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024June 17, 2024 | prnewswire.comCompugen to Present at Upcoming Antibody Industrial SymposiumSee More Headlines Receive CGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Compugen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CGEN CUSIPN/A CIK1119774 Webwww.cgen.com Phone(723) 765-8585Fax972-3765-8555Employees70Year Founded1993Price Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+118.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.19) Trailing P/E RatioN/A Forward P/E Ratio26.14 P/E GrowthN/ANet Income$-18,750,000.00 Net MarginsN/A Pretax Margin-1.19% Return on Equity-16.10% Return on Assets-9.23% Debt Debt-to-Equity RatioN/A Current Ratio4.12 Quick Ratio4.12 Sales & Book Value Annual Sales$42.72 million Price / Sales3.82 Cash FlowN/A Price / Cash FlowN/A Book Value$0.65 per share Price / Book2.82Miscellaneous Outstanding Shares89,240,000Free FloatN/AMarket Cap$163.31 million OptionableOptionable Beta2.65 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Anat Cohen-Dayag Ph.D. (Age 57)CEO, President & Director Comp: $796.52kDr. Zurit Levine Ph.D. (Age 56)Senior Vice President of Technology Innovation Comp: $345.7kDr. Pierre Ferre Ph.D. (Age 47)Vice President of Preclinical Development Comp: $415.1kMr. Alberto Sessa (Age 62)Chief Financial Officer Dr. Eran Ophir Ph.D. (Age 46)Chief Scientific Officer Ms. Yvonne NaughtonHead of Investor Relations & Corporate CommunicationsMr. Eran Ben DorGeneral Counsel & Corporate SecretaryMs. Dorit Amitay (Age 56)Vice President of Human Resources Dr. Yaron Turpaz M.B.A. (Age 53)Ph.D., Senior VP & Senior Advisor of Data and Informatics Solutions Rivka SchwartzVice President Research and DiscoveryMore ExecutivesKey CompetitorsCoherus BioSciencesNASDAQ:CHRSInhibrxNASDAQ:INBXTCR2 TherapeuticsNASDAQ:TCRRBlack Diamond TherapeuticsNASDAQ:BDTXC4 TherapeuticsNASDAQ:CCCCView All CompetitorsInstitutional OwnershipSquarepoint Ops LLCBought 16,253 shares on 8/14/2024Ownership: 0.099%Renaissance Technologies LLCSold 8,100 shares on 8/9/2024Ownership: 1.488%Rothschild Investment LLCBought 221,900 shares on 7/31/2024Ownership: 0.256%Taylor Frigon Capital Management LLCSold 7,298 shares on 7/29/2024Ownership: 0.000%ARK Investment Management LLCBought 48,979 shares on 7/26/2024Ownership: 0.000%View All Institutional Transactions CGEN Stock Analysis - Frequently Asked Questions How have CGEN shares performed this year? Compugen's stock was trading at $1.98 on January 1st, 2024. Since then, CGEN shares have decreased by 7.6% and is now trading at $1.83. View the best growth stocks for 2024 here. How were Compugen's earnings last quarter? Compugen Ltd. (NASDAQ:CGEN) issued its earnings results on Tuesday, August, 6th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.06. The biotechnology company had revenue of $6.70 million for the quarter, compared to analysts' expectations of $2.68 million. What is Anat Cohen-Dayag's approval rating as Compugen's CEO? 2 employees have rated Compugen Chief Executive Officer Anat Cohen-Dayag on Glassdoor.com. Anat Cohen-Dayag has an approval rating of 100% among the company's employees. This puts Anat Cohen-Dayag in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are Compugen's major shareholders? Top institutional shareholders of Compugen include Taylor Frigon Capital Management LLC, Renaissance Technologies LLC (1.49%), ARK Investment Management LLC and Rothschild Investment LLC (0.26%). How do I buy shares of Compugen? Shares of CGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Compugen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Compugen investors own include Oramed Pharmaceuticals (ORMP), NVIDIA (NVDA), Advanced Micro Devices (AMD), QUALCOMM (QCOM), AbbVie (ABBV) and Inovio Pharmaceuticals (INO). This page (NASDAQ:CGEN) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compugen Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CGEN Stock Alerts